Some 29,000 registrants descended on McCormick Place, the largest convention center in the United States, for the Society for Neuroscience annual meeting, held October 17-21 near downtown Chicago. Among the 18 symposia, 31 minisymposia, 98 nanosymposia, 650 poster sessions, and numerous special lectures was a shrinking but still lively fraction of Alzheimer’s science. Alzforum reporters Madolyn Rogers and Tom Fagan ferreted it out.
Basic science inspires conference goers in Chicago.
Research presented at SfN strengthens the case that microglia gorge on synapses in some neurodegenerative and neurodevelopmental disorders.
Researchers at SfN 2015 outlined perinatal treatments that rescued cognition in mouse models of the disease.
Two drugs that boost α-synuclein clearance have passed Phase 1 safety benchmarks, and a stem cell strategy is poised to enter trials, reported scientists at SfN 2015.
Scientists start to unravel role played by genetic risk variants.
Scientists at SfN offer alternate views of Bin1 biology.
Forget transgenics for a moment. Large collections of inbred and outbred mice could be an untapped treasure trove for Alzheimer’s researchers.
Researchers at this year’s SfN meeting detailed different strategies and outcomes of passive and active vaccines.
In various animal models of traumatic brain injury, acute treatments quiet inflammation and preserve neurons and their myelin sheaths.